Literature DB >> 22149874

HER2 therapy--an abundance of riches.

William J Gradishar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22149874     DOI： 10.1056/NEJMe1113641

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  23 in total

Review 1.  Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2012-02-12       Impact factor: 9.546

Review 2.  Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.

Authors:  Thuy Vu; Mark X Sliwkowski; Francois X Claret
Journal:  Biochim Biophys Acta       Date:  2014-07-25

3.  Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial.

Authors:  Lawrence G Lum; Archana Thakur; Zaid Al-Kadhimi; Gerald A Colvin; Francis J Cummings; Robert D Legare; Don S Dizon; Nicola Kouttab; Abby Maizel; William Colaiace; Qin Liu; Ritesh Rathore
Journal:  Clin Cancer Res       Date:  2015-02-16       Impact factor: 12.531

4.  Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

Authors:  Josep Lluís Parra-Palau; Beatriz Morancho; Vicente Peg; Marta Escorihuela; Maurizio Scaltriti; Rocio Vicario; Mariano Zacarias-Fluck; Kim Pedersen; Atanasio Pandiella; Paolo Nuciforo; Violeta Serra; Javier Cortés; José Baselga; Charles M Perou; Aleix Prat; Isabel T Rubio; Joaquín Arribas
Journal:  J Natl Cancer Inst       Date:  2014-09-24       Impact factor: 13.506

5.  Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study.

Authors:  Ines Vaz-Luis; Davinia Seah; Erin M Olson; Nikhil Wagle; Otto Metzger-Filho; Jessica Sohl; Georgia Litsas; Harold J Burstein; Ian E Krop; Eric P Winer; Nancy U Lin
Journal:  Clin Breast Cancer       Date:  2013-08       Impact factor: 3.225

Review 6.  Prevalence and role of HER2 mutations in cancer.

Authors:  Emiliano Cocco; Salvatore Lopez; Alessandro D Santin; Maurizio Scaltriti
Journal:  Pharmacol Ther       Date:  2019-04-02       Impact factor: 12.310

Review 7.  Second malignancies after breast cancer: The impact of adjuvant therapy.

Authors:  Chunhui Dong; Ling Chen
Journal:  Mol Clin Oncol       Date:  2014-02-03

Review 8.  Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

9.  Combination of intermittent calorie restriction and eicosapentaenoic acid for inhibition of mammary tumors.

Authors:  Nancy K Mizuno; Olga P Rogozina; Christine M Seppanen; D Joshua Liao; Margot P Cleary; Michael E Grossmann
Journal:  Cancer Prev Res (Phila)       Date:  2013-04-02

10.  Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer.

Authors:  Parvin F Peddi; Sara A Hurvitz
Journal:  Future Oncol       Date:  2013-03       Impact factor: 3.404
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.